On September 19, Menarini Silicon Biosystems introduced the launch of recent cloud-based knowledge evaluation resolution, MSBiosuite. MSBiosuite automated knowledge evaluation platform processes NGS knowledge generated from analysis in liquid biopsy space and formalin-fixed paraffin embedded (FFPE) tissue evaluation.
Menarini Silicon Biosystems partnered with BlueBee to develop this bioinformatics resolution. Bluebee is a world bioinformatics addressing knowledge evaluation wants in genomics and multiomics house. The corporate offers complete and optimised knowledge options to course of uncooked sequencing knowledge into actionable insights to drive large-scale translational analysis.
MSBiosuite offers improved NGS knowledge processing, interpretation, evaluation and reporting for uncooked sequencing knowledge generated with Menarini’s Ampli1 and DEPArray NGS kits for single circulating tumor cells (CTCs) and FFPE tissue evaluation respectively. It additionally offers info on somatic variation and duplicate quantity profile of a goal sequence. Although the launch of this options, Menarini goals to handle a number of challenges related to conventional bioinformatics options which incorporates complexity for knowledge administration and regulatory compliance. With MSBiosuite, completes Menarini’s single-cell liquid biopsy and FFPE workflows and can assist researchers to derive actionable insights with improved effectivity.
Menarini Silicon Biosystems grew to become pioneer in liquid biopsy area via acquisition of CELLSEARCH Circulating Tumor Cell System from Janssen Diagnostics, LLC. CellSearch is the primary clinically validated blood take a look at accredited by the U.S. Meals and Drug Administration for enumeration and detection of circulating tumor cells (CTCs) for sufferers with metastatic breast, prostate, and colorectal cancers. CTC evaluation aids within the early evaluation of affected person prognosis, thus proving its effectiveness within the therapy of the affected person and likewise offering useful info to make a scientific resolution. The scientific purposes of CTCs embrace the prediction of most cancers prognosis, choice, and the monitoring of therapeutic regimens and drug goal purposes.
The worldwide liquid biopsy market is projected to achieve USD 2,047.9 Million by 2022 from USD 715.7 Million in 2017, at a CAGR of 23.4%. Elements corresponding to growing prevalence of most cancers, growing choice for noninvasive procedures, initiatives undertaken by authorities and international well being organizations, technological developments to reinforce market revenues, rising emphasis on customized medication in scientific observe, and elevated funding for R&D are driving the expansion of the market. With big investments and rising proof of the makes use of/purposes of liquid biopsy, corporations are more and more seeking to transfer into the liquid biopsy market.
In keeping with Prachi Saxena, Senior Supervisor, Healthcare Analysis at MarketsandMarkets™, superior sequencing strategies corresponding to NGS are additionally contributing to the expansion of liquid biopsy market. Subsequent-generation sequencing (NGS) aids within the detection of low ranges of ctDNA within the bloodstream, because it affords sensitivity and specificity. Along with focusing on a single gene or a subset of genes, NGS may also determine genome-wide tumor-derived alterations in ctDNA.
The Subsequent-generation sequencing market is projected to achieve USD 16.35 billion by 2024 from USD 4.83 billion in 2017, at a CAGR of 19.2% throughout the forecast interval. Developments in NGS applied sciences over time have decreased the prices of sequencing platforms and programs in addition to the sequencing course of itself. This is likely one of the main drivers for the expansion of the NGS market. As well as, the regulatory and reimbursement outlook for NGS has improved steadily, thereby serving to spice up the adoption of sequencing applied sciences amongst a wider base of finish customers than earlier than. Many institutes desire NGS programs, which have overridden microarray expertise. The purposes of NGS in most cancers therapy and precision medication are additionally producing widespread curiosity. As costs are anticipated to lower additional within the coming years, NGS-based checks are anticipated to be thought of beneath medical health insurance insurance policies for reimbursement.
Nonetheless, whereas the prices concerned in NGS have decreased to some extent, they haven’t reached a degree the place broad adoption throughout creating markets might be achieved. It is a key restraint to market development. As well as, there’s a want for applied sciences to successfully analyze the advanced knowledge generated by NGS; that is each a problem for the market in its present state in addition to an space of alternative for market gamers
Key Gamers in NGS Market
1 Illumina, Inc.
2 Thermo Fisher Scientific Inc.
3 Perkinelmer, Inc.
Key Gamers in Liquid Biopsy Market
1 Qiagen N. V.
2. F. Hoffmann-La Roche AG
3 Illumina, Inc..
Supply: MarketsandMarkets™ Evaluation.
For extra info, please write to us at [email protected]
